000			02046cam a2200277 4500500
005			20260517000207.0
041			_afre
042			_adc
100	1	0	_aBlasco Perrin, Hélène _eauthor
700	1	0	_aGuivarch, Matthieu _eauthor
700	1	0	_aBerlioux, Pierre _eauthor
700	1	0	_aKaighobadi, Thibault _eauthor
700	1	0	_aBilley, Chloé _eauthor
700	1	0	_aHervieu, Pierre Emmanuel _eauthor
700	1	0	_aPointreau, Adeline _eauthor
700	1	0	_aAlric, Hadrien _eauthor
700	1	0	_aDupuis, Emmanuel _eauthor
700	1	0	_aLaroyenne, Alexia _eauthor
700	1	0	_aGuillaume, Maeva _eauthor
245	0	0	_a● Takeaways from issue 2, February 2026
260			_c2026.
500			_a41
520			_aThe BRAFV600E mutation, present in approximately 10% of metastatic colorectal cancers (mCRC), is associated with an aggressive phenotype and a historically poor prognosis. BRAF inhibition alone has proven ineffective in mCRC due to adaptive resistance mechanisms involving EGFR reactivation, leading to the development of combination strategies. The combination of encorafenib and cetuximab has thus become the standard second-line treatment following the BEACON study. The phase III BREAKWATER study, the results of which have been presented in recent months, demonstrates that in first-line treatment, the addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy in patients with BRAFV600E-mutated pMMR/MSS mCRC significantly improves response rate, progression-free survival, and overall survival compared to standard chemotherapy, with an acceptable safety profile. This strategy corrects the prognostic disadvantage of this subgroup and establishes the combination of encorafenib + cetuximab + mFOLFOX6 as the new first-line treatment standard for pMMR/MSS BRAFV600E-mutated mCRC.
786	0		_nHépato-Gastro & Oncologie Digestive | 33 | 3 | 2026-03-31 | p. 399-401 | 2115-3310
856	4	1	_uhttps://stm.cairn.info/journal-hepato-gastro-et-oncologie-digestive-2026-3-page-399?lang=en&redirect-ssocas=7080
999			_c2230117 _d2230117